List of 5 Acquisitions by Tempus (Jul 2026) - Tracxn

JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn.

Internal Server Error

Most viewed in 2019

Tempus has made a total of 5 acquisitions. These were completed across 7 distinct sectors, including Healthcare IT, Life Sciences Tech, and Artificial Intelligence, all within United States, totaling 1 country of operation. Peak activity occurred in 2025 with 2 deals, followed by 1 deal each in 2024 and 2023, resulting in an average of 1 acquisition per year from 2020–2025. There were 0 acquisitions in the current calendar year. The most recent acquisition is PAIGE, a developer of AI applications and foundation models for cancer diagnostics founded in 2018 and based in New York City, which was acquired in August 2025.

Here's the year on year acquisition history of Tempus:

Number of Total Acquisitions

Year	# Acquisitions
2025	2
2024	1
2023	1
2022	1

View all Acquisitions by Tempus

Recent acquisitions by Tempus

Tempus's most recent acquisition - PAIGE is a Developer of AI applications and foundation models for cancer diagnostics, founded in 2018 and located in New York City. Tempus acquired it in August 2025 for a price of $*****.

Here is the list of all acquisitions by Tempus sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Aug 22, 2025	PAIGE	btyv	wbsn	24	402
Mar 11, 2025	Deep 6 AI	rjpm	woqf	89	553
Nov 05, 2024	Ambry Genetics	vdfa	ynwj	46	499

View the full list of acquisitions

Sign Up for Free

Media has covered Tempus for a total of 105 events in the last 1 year, 19 of them have been about acquisition activity.

•

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and NeuroscienceBusiness Wire•May 14, 2026•Bristol-Myers Squibb, Tempus

•

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative MedicinesPR Newswire•May 12, 2026•Hengrui, Bristol-Myers Squibb, Tempus, Lonza

•

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical WorkflowsBusiness Wire•May 06, 2026•Lucent Diagnostics, Tempus

•

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision MedicineBusiness Wire•Apr 23, 2026•USC, Tempus

•

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD MonitoringTempus•Apr 15, 2026•Tempus, Predicta Biosciences

•

One-carbon Therapeutics partners with Tempus in cancer treatmentPMLiVE•Apr 13, 2026•One-carbon Therapeutics, Tempus

•

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWEBusiness Wire•Apr 09, 2026•Gilead, Tempus

•

Tempus, Median Technologies Collaborate on AI-Powered Lung Cancer ScreeningMedical Product Outsourcing•Apr 09, 2026•Tempus, Median

•

One-carbon Therapeutics Signs Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619Media Bulletins•Mar 17, 2026•One-carbon Therapeutics, Tempus,

•

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United StatesBusiness Wire•Feb 13, 2026•Tempus, Median

View More Tempus Recent News

View all Acquisitions by Tempus

Tracxn powers 1,000+ customers across 30+ countries